Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. (Q48743328)

15 February 2018

title

Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. (English)

1 reference

15 February 2018

1 reference

3

1 reference

15 February 2018

author name string

Anita Villani

series ordinal

1

1 reference

15 February 2018

David Malkin

series ordinal

2

1 reference

15 February 2018

publication date

1 April 2012

1 reference

15 February 2018

Current Neurology and Neuroscience Reports

published in

1 reference

15 February 2018

volume

12

1 reference

15 February 2018

page(s)

153-164

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

https://scigraph.springernature.com/pub.10.1007/s11910-011-0244-5

exact match

0 references

cites work

TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Neurofibromatosis type 1 revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Prognostic factors for progression of childhood optic pathway glioma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Neurofibromatosis type 1 and high-grade tumors of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The hedgehog signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Mutations in SUFU predispose to medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Nevoid basal cell carcinoma (Gorlin) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Neurooncology of familial cancer syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Targeting Hedgehog--a cancer stem cell pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Medulloblastoma comprises four distinct molecular variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The tuberous sclerosis complex: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The Fanconi anaemia/BRCA pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Genotype-phenotype correlations in Fanconi anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Expression of p53 and prognosis in children with malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Brain tumor-polyposis syndrome: two genetic diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Hypothesis: Possible role of retinoic acid therapy in patients with biallelic mismatch repair gene defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Hereditary and familial colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Pineoblastoma presenting in familial adenomatous polyposis (FAP): random association, FAP variant or Turcot syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The molecular basis of Turcot's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

The adenomatous polyposis coli tumor suppressor and Wnt signaling in the regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Neurofibromatosis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Management of the patient and family with neurofibromatosis 2: a consensus conference statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Presymptomatic genetic testing in children for neurofibromatosis 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

von Hippel-Lindau disease: a clinical and scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

PTEN hamartoma tumor syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Cowden syndrome: a critical review of the clinical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

PTEN hamartoma tumor syndrome: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Tumors in Rubinstein-Taybi syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Ataxia-telangiectasia and related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

ATM and ataxia telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Relative frequency and morphology of cancers in carriers of germline TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Empirical development of improved diagnostic criteria for neurofibromatosis 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0244-5

National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987

21 January 2018

1 reference

12 December 2020

Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.

1 reference

12 December 2020

The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes

1 reference

12 December 2020

The ATM gene and ataxia telangiectasia

1 reference

12 December 2020

2009 Version of the Chompret Criteria for Li Fraumeni Syndrome

1 reference

12 December 2020

Epidemiology of tuberous sclerosis

1 reference

12 December 2020

Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome

1 reference

12 December 2020

Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex

1 reference

12 December 2020

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.

1 reference

12 December 2020

Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1.

1 reference

12 December 2020

10.1007/S11910-011-0244-5

Identifiers

DOI

1 reference

15 February 2018

PubMed ID

22205236

1 reference

15 February 2018